VALHomo sapiens (Human)Cancer cell line

🤖 AI SummaryBased on 8 publications

Quick Overview

Human B-cell lymphoma cell line with MYC and BCL2 rearrangements

Detailed Summary

The VAL cell line is a human B-cell lymphoma cell line derived from a patient with non-Hodgkin lymphoma. It is characterized by the presence of MYC and BCL2 gene rearrangements, which are associated with aggressive clinical behavior and poor prognosis. This cell line has been used in research to study the molecular mechanisms underlying double-hit lymphomas and to develop targeted therapies. VAL is part of a panel of cell lines that have been extensively characterized for their genetic and molecular profiles, making them valuable tools for understanding lymphomagenesis and testing novel therapeutic strategies.

Research Applications

Study of double-hit lymphomasInvestigation of MYC and BCL2 rearrangementsDevelopment of targeted therapiesMolecular mechanisms of lymphomagenesis

Key Characteristics

MYC and BCL2 gene rearrangementsAggressive clinical behaviorPoor prognosisPart of a well-characterized cell line panel

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1819
Species	Homo sapiens (Human)
Tissue Source	Bone marrow[UBERON:UBERON_0002371]

Donor Information

Age	50
Age Category	Adult
Sex	Female

Disease Information

Disease	Diffuse large B-cell lymphoma
Lineage	Lymphoid
Subtype	Diffuse Large B-Cell Lymphoma, NOS
OncoTree Code	DLBCLNOS

DepMap Information

Source Type	DSMZ
Source ID	ACH-001703_source

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

10,12

D13S317

10,14

D16S539

9,13

D18S51

14,16,17

D19S433

13,14

D21S11

27,30

D2S1338

20,23

D3S1358

17,19

D5S818

D7S820

D8S1179

11,12

FGA

22,24

Penta D

Penta E

TH01

6,9

TPOX

vWA

14,15

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

DOI PubMed PMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.

Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.

Leuk. Lymphoma 57:1015-1020(2016).

DOI PubMed

Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.

Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.

J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).

DOI PubMed PMC

Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.

Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.

Int. J. Cancer 125:212-221(2009).

DOI PubMed

Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.

Martinez-Climent J.A.

Blood 109:271-280(2007).

DOI PubMed

The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.

Quentmeier H., Drexler H.G.

Leukemia 10:142-149(1996).

PubMed

LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas.

Bastard C.

Nat. Genet. 5:66-70(1993).

DOI PubMed

Web Resources

tcpaportal.org